This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders. Speakers will provide an overview of the current and evolving coverage and treatment landscapes for Hemophilia, Sickle Cell, and Beta Thalassemia.
This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on The Role of BTKi’s in the Management of CLL. Speakers will provide an overview of the current and evolving coverage and treatment landscapes for managing CLL.
In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
January 2023 Legislative & Regulatory Briefing: The PIE Act of 2022 Becomes Law; Member Benefit! Stay Up to Date on IRA Guidance with Regulatory NewsBREAKs; Media Coverage Captures Its Own Piece of the PIE; Reimbursement for PDTs Could Increase Access to Emerging Treatments; Registration is Now Open for AMCP 2023 in San Antonio.
Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.
On Nov. 9, 2022, Cliff Goodman, PhD, moderated the AMCP Summit on value-based arrangements. He provides his key takeaways from the virtual event in the latest guest blog.
By Cliff Goodman, PhD, AMCP Summit Moderator, The Lewin Group • 1/4/23